Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | First-line treatment of SAA: towards a new standard of care?

Regis Peffault de Latour • 15 Jun 2019
EHA 2019
Anemias Aplastic Anemia Cyclosporine Eltrombopag Horse antithymocyte globulin
Race

Regis Peffault de Latour, MD, PhD, Saint Louis Hospital, Paris, France, discusses novel combination therapies for the treatment of severe aplastic anemia (SAA). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Regis Peffault de Latour

2:55
RACE: evaluating eltrombopag in severe aplastic anemia
Regis Peffault de Latour • 3 Sep 2020
1:17
Overview of HSCT and GvHD at EBMT
Regis Peffault de Latour • 3 Sep 2020
2:01
Eltrombopag for aplastic anaemia in Europe
Regis Peffault de Latour • 1 Sep 2020
2:21
LNP023 for paroxysmal nocturnal hemoglobinuria
Regis Peffault de Latour • 2 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
2:13
SATISFY: mitapivat in patients with erythrocyte membranopathies
Kevin Kuo • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals